Genmab — November 2024
-
Genmab's operating profit significantly beats expectations, raises forecasts https://www.marketscreener.com/quote/stock/GENMAB-A-S-63733191/news/Genmab-s-operating-profit-significantly-beats-expectations-raises-forecasts-48276184/
-
ChatGPT om gen1078: Genmab's GEN1078 is an investigational monoclonal antibody currently under development with a focus on autoimmune diseases, particularly rheumatoid arthritis (RA). GEN1078 targets c5a, a component of the complement system, which is part of the immune response. Specifically, GEN1078 binds to C5a receptor 1 (C5aR), blocking its activation and downstream inflammatory signaling. By inhibiting C5a, which plays a significant role in driving inflammation and tissue damage
-
As of now, GEN1078 has entered clinical trials to evaluate its safety, tolerability, and efficacy. Early-stage trials have shown promising results, with the drug being well-tolerated and demonstrating a reduction in markers of inflammation. Genmab and its development partner, Janssen Pharmaceuticals, are likely focusing on optimizing dosing, expanding clinical trials to different patient populations, and assessing its long-term effects and potential for combination with other treatments.
-
Genmabs guldæg sørger for fortsat vækst og oppræcisering https://proinvestor.com/investornyt/1238683/genmabs-guldaeg-sorger-for-fortsat-vaekst-og-oppraecisering
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind